Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 14 images provide visual information about the product associated with Levetiracetam NDC 55150-246 by Eugia Us Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

This appears to be a statistical report outlining the percentage of patients in a study who received Placebo or varying doses of the drug Levetiracetam (at 1,000 and 3,000 mg/day), with indication of statistically significant results. There does not seem to be enough context to provide a more specific description.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig10

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig10

Levetiracetam is a prescription drug used for intravenous infusion to treat seizures in patients. It is available in single-dose bags with a concentration of 1,000 mg per 100 mL, recommended for use only with a calibrated infusion device. The package contains ten 100 mL bags of the drug, which should not be further diluted before use. The drug is buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate. Users are advised to check for minute leaks after removing the overwrap and discard the container if any leaks are found. The recommended storage temperature is between 20 and 25 degrees Celsius.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Infusion Bag Label - levetiracetam fig11

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Infusion Bag Label - levetiracetam fig11

This is a description of a medication called Levetiracetam Sodium Chloride Injection. It is an intravenous infusion used for the treatment of certain types of seizures. The container holds 100 mL of the solution, containing 1,500 mg of the active ingredient, Levetiracetam USP, buffered with glacial acetic acid and sodium acetate. The prescribed dosage should be followed, and caution must be taken to not use containers with leaks or damages. The medication should be used promptly with an infusion device; storage should be at 20-25°C (68-77°F). The text seems to emphasize guidelines for proper usage and storage.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig12

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig12

This is a 100 mL bag of Levetiracetam in 0.54% Sodium Chloride Injection used for Intravenous Infusion Only. It contains 1500 mg of Levetiracetam USP (15 mg/mL), water for injection, 540 mg of sodium chloride, 7.5 mg of lactic acid, and is buffered at approximately pH 5.5 with glacial acetic acid and 164 mg of sodium acetate tihycrate. The medication should not be further diluted prior to use and must be infused over a period of 15 minutes. The bag has dual ports, and the overwrap must not be opened or damaged before use. It is recommended to store this medication at 20°C to 25°C (63°F to 77°F). Made in India by Aurobindo Pharma LLC.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig13

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,500 mg per 100 mL (15 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig13

Levetiracetam is a medication that is available in a 0.54% sodium chloride injection with a strength of 1,500 mg per 100 mL (15 mg/mL). It is meant to be used for intravenous infusion only and comes in 10 x 100 mL single-dose bags. Each bag should be infused over 15 minutes using a calibrated infusion device. The solution contains levetiracetam USP (15 mg/mL), sodium chloride, and other ingredients that have been buffered to pH 5.5 using glacial acetic acid. The medication should not be further diluted before use and caution should be taken to ensure there are no leaks before use. If any leaks are found, the container should be discarded. The medication should be stored at 20°C to 25°C (68°F to 77°F). The medication is distributed by AuroMedics Pharma LLC and made in India. Dosage information should be obtained from prescribing information.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

The text is providing results of a study that compared the efficacy of a placebo group against two other groups treated with different dosages of Levetiracetam. The percentages indicate the level of statistical significance found in the results of the study.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

This text provides the percentage of patients who were administered Lovetiracetam in comparison with those who received the placebo. Lovetiracetam was administered at a dose of 3,000 mg/day and showed statistical significance when compared to the outcomes of the placebo group. However, there is not enough information to determine what the study was for or what specific outcomes were being measured.*

Figure 4: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week - levetiracetam fig4

Figure 4: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week - levetiracetam fig4

This is a statistical data comparison of the effectiveness of Levetiracetam versus Placebo in treating a certain medical condition. Both treatment groups had a sample with 84 patients and 79 patients respectively. The data is presented as percentages of patients and shows a statistically significant difference in effectiveness between Levetiracetam and Placebo.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Infusion Bag Label - levetiracetam fig5

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Infusion Bag Label - levetiracetam fig5

Levetiracetam is a medication available in a single-dose dual port bag with NDC 55150-246-47, containing 500 mg per 100 mL (5 mg/mL) in 0.82% Sodium Chloride Injection for intravenous infusion only. Each 100 mL contains 820 mg sodium chloride, 5.5 mg of glacial acetic acid, and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate ribotril. The medication should not be further diluted, and caution is advised not to use plastic containers in series connections. The usual dosage should be obtained from the prescribing information. The medication should be used only with a calibrated infusion device, and the unit should be promptly used once the overwrap is removed. The recommended storage temperature is within 20° to 25° C and should be stored away from the reach of children.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig6

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig6

Levetiracetam is an intravenous medication, intended for infusion use only, available in a 100 mL size. The medication is a USP grade formulation that contains 500mg of levetiracetam or 5mg/mL in 0.82% sodium chloride injection. The ideal period to infuse Levetiracetam over is 15 minutes, and it should not be further diluted before use. Each 100 mL of the medication contains 80mg of sodium chloride, 5.5g of glacial acetate, buffered with glacial acetic acid, and 164mg of sodium acetate trihydrate. Dosage is dependent on prescription information. Do not use plastic containers in series connections. Use only with a calibrated infusion device. The bag is a single-dose dual-port type with an aluminum overwrap, and the container closure does not contain natural rubber latex. It is recommended to store it at 20°C to 25°C (66°F to 77°F) with the unit being discarded if unused. Tear at the notch to open, and the product should be used immediately if the overwrap is removed, and it has not been previously opened or damaged. The medication was distributed by AuroMedics Pharma LLC, and the product is made in India.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 100 mL (5 mg / mL) - Container-Carton Label (10 Pouches) - levetiracetam fig7

Levetiracetam is a medication available in a single-dose bag used for intravenous infusion only. Each 100 mL contains 500 mg of levetiracetam, 0.82% Sodium Chloride injection, water for injection, 820 mg sodium chloride, 5.5 mg glacial acetic acid, and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate. The infusion should be done over a period of 15 minutes with a calibrated infusion device. The container closure is not made with natural rubber latex. Recommended storage is at 20° to 25°C (68° to 77°F) in a controlled room temperature, and the single-dose dual portbag with aluminum overwrap should be discarded after its use. The usual dosage should be determined from the prescribing information, and the container must be checked for minute leaks before use. Do not use plastic containers in series connections, and Levetiracetam in 0.82% Sodium Chloride injection should not be further diluted before use. The product is distributed by AuroMedics Pharma LLC, made in India, and its code is TS/DRUGS/01/2013/LVP.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Infusion Bag Label - levetiracetam fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Infusion Bag Label - levetiracetam fig8

This is a description of Levetiracetam, which is available in a 100mL bottle containing 1,000 mg per 100 mL (10 mg/mL) of Levetiracetam. It is an injectable solution designed for intravenous infusion and must be infused over a period of 15 minutes. The solution also includes 750 mg of sodium chioride, 6.5 mg of glacial acetic acid, and is buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate. It should not be used with plastic containers. The drug comes in a single-dose dual-port bag, and the unused portion should be discarded. It is recommended to store this drug at 20°C to 25°C (68°F to 77°F).*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig9

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1,000 mg per 100 mL (10 mg / mL) - Pouch (Overwrap) Label - levetiracetam fig9

This is a package insert for Levetiracetam in 0.75% Sodium Chloride Injection. The 1,000 mg per 100 mL solution is for intravenous infusion only and manufactured by Auromedics. The usual dosage instructions are not available in the scanned text. It comes with a caution to avoid damage to the container and the medication is to be stored at controlled room temperature. There is also contact information for the manufacturer.*

Levetiracetam Chemical Structure - levetiracetam str

Levetiracetam Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.